These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29171305)

  • 1. Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis.
    Nishida Y; Hosomi S; Watanabe K; Watanabe K; Yukawa T; Otani K; Nagami Y; Tanaka F; Taira K; Kamata N; Yamagami H; Tanigawa T; Watanabe T; Fujiwara Y
    Scand J Gastroenterol; 2018 May; 53(5):579-585. PubMed ID: 29171305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in cytokine profile may predict therapeutic efficacy of infliximab in patients with ulcerative colitis.
    Sato S; Chiba T; Nakamura S; Matsumoto T
    J Gastroenterol Hepatol; 2015 Oct; 30(10):1467-72. PubMed ID: 25968585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.
    Lacruz-Guzmán D; Torres-Moreno D; Pedrero F; Romero-Cara P; García-Tercero I; Trujillo-Santos J; Conesa-Zamora P
    Eur J Clin Pharmacol; 2013 Mar; 69(3):431-8. PubMed ID: 22960943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.
    Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J
    Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.
    Iwasa R; Yamada A; Sono K; Furukawa R; Takeuchi K; Suzuki Y
    BMC Gastroenterol; 2015 Aug; 15():103. PubMed ID: 26271624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
    Papamichael K; Rivals-Lerebours O; Billiet T; Vande Casteele N; Gils A; Ferrante M; Van Assche G; Rutgeerts PJ; Mantzaris GJ; Peyrin-Biroulet L; Vermeire S
    J Crohns Colitis; 2016 Sep; 10(9):1015-23. PubMed ID: 27022161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.
    Lee KM; Jeen YT; Cho JY; Lee CK; Koo JS; Park DI; Im JP; Park SJ; Kim YS; Kim TO; Lee SH; Jang BI; Kim JW; Park YS; Kim ES; Choi CH; Kim HJ;
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1829-33. PubMed ID: 23829336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis.
    Wine E; Mack DR; Hyams J; Otley AR; Markowitz J; Crandall WV; Leleiko N; Muise AM; Griffiths AM; Turner D
    J Crohns Colitis; 2013 Dec; 7(11):916-22. PubMed ID: 23339932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
    Billiet T; Cleynen I; Ballet V; Claes K; Princen F; Singh S; Ferrante M; Van Assche G; Gils A; Vermeire S
    Scand J Gastroenterol; 2017 Oct; 52(10):1086-1092. PubMed ID: 28622097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.
    Magnusson MK; Strid H; Isaksson S; Bajor A; Lasson A; Ung KA; Öhman L
    J Crohns Colitis; 2015 Jan; 9(1):56-65. PubMed ID: 25518051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.
    Baird AC; Mallon D; Radford-Smith G; Boyer J; Piche T; Prescott SL; Lawrance IC; Tulic MK
    World J Gastroenterol; 2016 Nov; 22(41):9104-9116. PubMed ID: 27895398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IMPORTANCE OF MEASURING LEVELS OF INFLIXIMAB IN PATIENTS TREATING INFLAMMATORY BOWEL DISEASE IN A BRAZILIAN COHORT.
    Kampa KC; Morsoletto DBG; Loures MR; Pissaia A; Nones RB; Ivantes CAP
    Arq Gastroenterol; 2017 Dec; 54(4):333-337. PubMed ID: 28954041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis.
    Nishida Y; Hosomi S; Yamagami H; Yukawa T; Otani K; Nagami Y; Tanaka F; Taira K; Kamata N; Tanigawa T; Shiba M; Watanabe K; Watanabe T; Tominaga K; Fujiwara Y
    PLoS One; 2017; 12(1):e0169845. PubMed ID: 28076386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
    Adedokun OJ; Sandborn WJ; Feagan BG; Rutgeerts P; Xu Z; Marano CW; Johanns J; Zhou H; Davis HM; Cornillie F; Reinisch W
    Gastroenterology; 2014 Dec; 147(6):1296-1307.e5. PubMed ID: 25173754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of induction therapy with infliximab in children with moderate to severe ulcerative colitis: a multi-center study.
    Szychta M; Wiernicka A; Dądalski M; Landowski P; Klincewicz B; Karolewska-Bochenek K; Czaja-Bulsa G; Jarocka-Cyrta E; Korczowski B; Sladek M; Kierkus J
    Dev Period Med; 2016; 20(3):205-211. PubMed ID: 27941190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction and maintenance infliximab therapy in children with moderate to severe ulcerative colitis: Retrospective, multicenter study.
    Iwańczak BM; Kierkuś J; Ryżko J; Szczepanik M; Więcek S; Czaja-Bulsa G; Kacperska M; Korczowski B; Maślana J; Iwańczak F
    Adv Clin Exp Med; 2017; 26(1):57-61. PubMed ID: 28397433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.
    Farkas K; Rutka M; Golovics PA; Végh Z; Lovász BD; Nyári T; Gecse KB; Kolar M; Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Malickova K; Bálint A; Nagy F; Bor R; Milassin Á; Szepes Z; Palatka K; Lakatos PL; Lukas M; Molnár T
    J Crohns Colitis; 2016 Nov; 10(11):1273-1278. PubMed ID: 27106537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis.
    Ierardi E; Giorgio F; Zotti M; Rosania R; Principi M; Marangi S; Della Valle N; De Francesco V; Di Leo A; Ingrosso M; Panella C
    J Clin Pathol; 2011 Nov; 64(11):968-72. PubMed ID: 21945924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.